Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZ-2053 for prophylaxis of acute pulmonary allograft rejection
NCT00105183Phase 3Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Jan 2005
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of grafalon in lung transplant rejection, sponsored by Neovii Pharmaceuticals. Started Jan 2005; status: completed.
02
Drugs
grafalon
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT00105183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105183.